Stralem & Co’s Thermo Fisher Scientific TMO Stock Holding History

Stralem & Co’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$3.97M	Sell	10,950 -123	-1%	-$41.2K	2.53%	24
2020 Q1	$3.14M	Sell	11,073 -1,120	-9%	-$353K	2.33%	30
2019 Q4	$3.96M	Sell	12,193 -5,370	-31%	-$1.63M	2.22%	33
2019 Q3	$5.12M	Sell	17,563 -137	-0.8%	-$39.2K	2.95%	18
2019 Q2	$5.2M	Sell	17,700 -4,490	-20%	-$1.24M	2.83%	21
2019 Q1	$6.07M	Sell	22,190 -555	-2%	-$138K	2.78%	23
2018 Q4	$5.09M	Sell	22,745 -14,195	-38%	-$3.33M	2.43%	26
2018 Q3	$9.02M	Sell	36,940 -3,870	-9%	-$890K	2.68%	24
2018 Q2	$8.45M	Sell	40,810 -25,000	-38%	-$5.31M	2.49%	27
2018 Q1	$13.6M	Sell	65,810 -7,680	-10%	-$1.61M	2.7%	25
2017 Q4	$14M	Sell	73,490 -4,245	-5%	-$813K	2.37%	28
2017 Q3	$14.7M	Sell	77,735 -26,960	-26%	-$4.88M	2.12%	32
2017 Q2	$18.3M	Sell	104,695 -4,070	-4%	-$684K	2.14%	29
2017 Q1	$16.7M	Sell	108,765 -9,420	-8%	-$1.44M	1.95%	33
2016 Q4	$16.7M	Sell	118,185 -7,030	-6%	-$1.04M	1.99%	33
2016 Q3	$19.9M	Sell	125,215 -2,570	-2%	-$396K	2.31%	27
2016 Q2	$18.9M	Sell	127,785 -11,475	-8%	-$1.69M	2.18%	32
2016 Q1	$19.7M	Sell	139,260 -13,454	-9%	-$1.8M	2.16%	31
2015 Q4	$21.7M	Sell	152,714 -53,900	-26%	-$7.19M	2.19%	30
2015 Q3	$25.3M	Sell	206,614 -27,745	-12%	-$3.61M	2.1%	30
2015 Q2	$30.4M	Sell	234,359 -53,091	-18%	-$6.92M	2.09%	33
2015 Q1	$38.6M	Sell	287,450 -153,230	-35%	-$19.8M	2.16%	32
2014 Q4	$55.2M	Sell	440,680 -86,390	-16%	-$10.5M	2.56%	26
2014 Q3	$64.1M	Sell	527,070 -127,283	-19%	-$15.5M	2.58%	25
2014 Q2	$77.2M	Sell	654,353 -66,667	-9%	-$7.85M	2.63%	26
2014 Q1	$86.7M	Sell	721,020 -121,051	-14%	-$14.4M	2.74%	25
2013 Q4	$93.8M	Sell	842,071 -129,487	-13%	-$12.9M	2.81%	25
2013 Q3	$89.5M	Sell	971,558 -109,560	-10%	-$9.91M	2.73%	24
2013 Q2	$91.5M	Buy	+1,081,118	New	+$90M	2.77%	26

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stralem & Co's TMO Position: Q2 2020 in Review

Stralem & Co reduced its Thermo Fisher Scientific (TMO) stake by 1.1% in Q2 2020, selling an estimated $41.2K and leaving 10,950 shares worth $3.97M. The position accounts for 2.53% of the portfolio, ranked #24.

Stralem & Co first reported a position in TMO in Q2 2013 and has held it in 29 quarters since. The position peaked at $93.8M in Q4 2013. 1,749 funds tracked by Wall St. Rank hold TMO as of Q2 2020.

Stralem & Co held 10,950 shares of Thermo Fisher Scientific worth $3.97M as of Q2 2020.
Stralem & Co sold 123 Thermo Fisher Scientific shares in Q2 2020, an estimated $41.2K.
Thermo Fisher Scientific made up 2.53% of Stralem & Co's portfolio in Q2 2020, its #24 holding.
Stralem & Co first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 29 quarters since.
Stralem & Co's Thermo Fisher Scientific position peaked at $93.8M in Q4 2013.
1,749 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2020.

Based on Stralem & Co's 13F filing for Q2 2020, filed 20 Jul 2020.